Development of a Universal Nasal Spray Vaccine

Development of a Universal Nasal Spray Vaccine

A recent breakthrough by Stanford University researchers has led to the development of a universal nasal spray vaccine, a mucosal vaccine administered through the nose rather than injection. It targets multiple respiratory pathogens including SARS-CoV-2, Influenza A/B, and Streptococcus pneumoniae. The vaccine uses synthetic nanoparticles and immune-boosting adjuvants to activate IgA (Immunoglobulin A) antibodies at mucosal surfaces such as the nasal lining, which act as the body’s first line of defence by neutralizing pathogens before they reach the lungs.

Historically, most vaccines have been injectable and focus on generating systemic immunity (IgG antibodies). However, respiratory infections enter through mucosal surfaces, leading to growing interest in mucosal vaccines. Earlier nasal vaccines (e.g., for influenza) showed promise but had limited scope. This new “universal” approach represents a shift toward broad-spectrum, frontline immunity rather than pathogen-specific protection.